Abvc Biopharma (ABVC) Share-based Compensation (2010 - 2026)
Abvc Biopharma's (ABVC) quarterly Share-based Compensation came in at $507041.0 in Q2 2026, down 67.74% on a YoY basis from $1.6 million in Q2 2025, and down 35.6% quarter-over-quarter from $787374.0 in Q1 2026.
Powered by 
Analysis
Abvc Biopharma (ABVC) Share-based Compensation (2010 - 2026) Analysis & Trends
Abvc Biopharma (ABVC) has reported Share-based Compensation for 14 consecutive years, with $507041.0 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Share-based Compensation fell 67.74% year-over-year to $507041.0; the trailing twelve-month figure through Jun 2026 stood at $2.7 million (up 11.45% YoY), and the FY2025 full-year result was $7.7 million, up 176.55% from the prior year.
- Share-based Compensation fell to $507041.0 in Q2 2026 per ABVC's latest filing, from $787374.0 in the prior quarter.
- Across five years, Share-based Compensation topped out at $4.7 million in Q1 2022 and bottomed at -$873321.0 in Q4 2023.
- Historically, Share-based Compensation has averaged $914851.7 across 5 years, with a median of $366489.0 in 2023.
- The sharpest annual moves came in 2022 and 2023: Share-based Compensation surged 1978.5% in 2022, then plunged 146.13% in 2023.
- Over 5 years, Share-based Compensation stood at $1.9 million in 2022, then plunged by 146.13% to -$873321.0 in 2023, then surged by 141.57% to $363079.0 in 2024, then soared by 288.68% to $1.4 million in 2025, then slumped by 64.07% to $507041.0 in 2026.
- According to Business Quant data, Share-based Compensation over the past three periods registered $507041.0, $787374.0, and $1.4 million for Q2 2026, Q1 2026, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 247.00 Mn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 231.00 Mn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 108.10 Mn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 243.00 Mn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 120.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 86.63 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 77.40 Mn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 83.34 Mn |
| 10 | Abvc Biopharma | 25.56 Mn | 25.56 Mn | - | 507,041.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 507,041.00 |
| Mar 31, 2026 | 787,374.00 |
| Sep 30, 2025 | 1.41 Mn |
| Jun 30, 2025 | 1.57 Mn |
| Mar 31, 2025 | 210,040.00 |
| Dec 31, 2024 | 363,079.00 |
| Sep 30, 2024 | 258,710.00 |
| Jun 30, 2024 | 282,875.00 |
| Mar 31, 2024 | 2.59 Mn |
| Dec 31, 2023 | -873,321.00 |
| Sep 30, 2023 | 817,740.00 |
| Jun 30, 2023 | 225,740.00 |
| Mar 31, 2023 | 366,489.00 |
| Dec 31, 2022 | 1.89 Mn |
| Sep 30, 2022 | 225,740.00 |
| Jun 30, 2022 | 225,740.00 |
| Mar 31, 2022 | 4.69 Mn |
| Dec 31, 2021 | 4.38 Mn |
| Sep 30, 2021 | 225,740.00 |
| Jun 30, 2021 | 475,740.00 |